Adiponectin agonist (PEG)-BHD1028 significantly reduced insulin c-peptide in insulin-resistant adults.
A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study of Adiponectin Agonist (PEG)-BHD1028 in People With Insulin Resistance.
Abstract
(PEG)-BHD1028, an adiponectin agonist, significantly reduced insulin c-peptide AUC by 63% at 8 µg/kg in insulin-resistant adults, showing dose-related exposure and good tolerability.